Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements.
Bonifacio M, Scaffidi L, Miggiano MC, Facchinelli D, Tosoni L, Pezone S, Griguolo D, Ciotti G, Danini M, Bernardelli A, Bresciani R, Cavraro M, Crosera L, De March E, Dell'Eva M, Dorotea L, Frison L, Furlani L, Gianesello I, Lovato E, Marchetti E, Morelli G, Mullai R, Pizzano U, Zoletto S, Fanin R, Krampera M, Trentin L, Calistri E, Carli G, Binotto G, Tiribelli M. Bonifacio M, et al. Among authors: krampera m. Blood Cancer J. 2024 Mar 26;14(1):53. doi: 10.1038/s41408-024-01025-7. Blood Cancer J. 2024. PMID: 38531834 Free PMC article. No abstract available.
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
Bonifacio M, Binotto G, Maino E, Calistri E, Marin L, Scaffidi L, Frison L, De Marchi F, Krampera M, Semenzato G, Fanin R, Ambrosetti A, Tiribelli M; Gruppo Triveneto LMC. Bonifacio M, et al. Among authors: krampera m. Haematologica. 2015 Aug;100(8):e299-301. doi: 10.3324/haematol.2015.124685. Epub 2015 Mar 27. Haematologica. 2015. PMID: 25820333 Free PMC article. No abstract available.
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients.
Tiribelli M, Bonifacio M, Binotto G, Iurlo A, Cibien F, Maino E, Guella A, Festini G, Minotto C, De Biasi E, De Marchi F, Scaffidi L, Frison L, Bucelli C, Medeot M, Calistri E, Sancetta R, Stulle M, Orofino N, Krampera M, Gherlinzoni F, Semenzato G, Pizzolo G, Ambrosetti A, Fanin R. Tiribelli M, et al. Among authors: krampera m. Oncotarget. 2018 Feb 12;9(18):14219-14227. doi: 10.18632/oncotarget.24478. eCollection 2018 Mar 6. Oncotarget. 2018. PMID: 29581839 Free PMC article.
Primary sphenoid lymphoma: Focus on imaging.
Facchinelli D, Boninsegna E, Barillari M, Mansueto G, Krampera M, Veneri D. Facchinelli D, et al. Among authors: krampera m. Tumori. 2018 Dec;104(6):NP42-NP45. doi: 10.1177/0300891618803501. Epub 2018 Oct 1. Tumori. 2018. PMID: 30270769
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy.
Bonifacio M, Scaffidi L, Binotto G, Miggiano MC, Danini M, Minotto C, Griguolo D, Marin L, Frison L, D'Amore F, Basso M, Sartori R, Tinelli M, Stulle M, Fortuna S, Bonalumi A, Bertoldero G, De Biasi E, Ruggeri M, Semenzato G, Fanin R, Pizzolo G, Krampera M, Tiribelli M. Bonifacio M, et al. Among authors: krampera m. Leuk Res. 2018 Nov;74:75-79. doi: 10.1016/j.leukres.2018.09.018. Epub 2018 Oct 2. Leuk Res. 2018. PMID: 30308414 Clinical Trial.
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.
Palandri F, Palumbo GA, Abruzzese E, Iurlo A, Polverelli N, Elli E, Bonifacio M, Bergamaschi M, Martino B, Tiribelli M, Benevolo G, Tieghi A, Sgherza N, Isidori A, Binotto G, Crugnola M, Heidel F, Cavazzini F, Bosi C, Auteri G, Cattaneo D, Foà R, Lemoli RM, Cuneo A, Krampera M, Bartoletti D, Cavo M, Vianelli N, Breccia M, Latagliata R. Palandri F, et al. Among authors: krampera m. Hematol Oncol. 2019 Oct;37(4):418-423. doi: 10.1002/hon.2619. Epub 2019 Jun 7. Hematol Oncol. 2019. PMID: 30985017
208 results